← 返回

高剂量雄激素通过改变 AR/circFKBP5/miRNA-513a-5p/PD-L1 信号抑制去势抵抗性前列腺癌细胞的 NK 细胞毒性

英文原题:High dose androgen suppresses natural killer cytotoxicity of castration-resistant prostate cancer cells via altering AR/circFKBP5/miRNA-513a-5p/PD-L1 signals.

查看英文原题

High dose androgen suppresses natural killer cytotoxicity of castration-resistant prostate cancer cells via altering AR/circFKBP5/miRNA-513a-5p/PD-L1 signals.

PubMed 2022/08/29(内容时间) Cell Death Dis Q1 · IF 12.2(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

大多数晚期前列腺癌(PCa)患者最初对雄激素剥夺治疗反应良好,但几乎所有患者最终都会发展为去势抵抗性前列腺癌(CRPC)。早期研究表明,通过高剂量和低剂量雄激素循环使用的双相雄激素治疗来抑制PCa生长,可能在特定患者群体中有效。

然而,其详细机制仍不清楚。在此,我们发现自然杀伤(NK)细胞抑制CRPC细胞的能力可被高剂量双氢睾酮(DHT)所抑制。机制解析表明,反式激活的AR可增加circularRNA-FKBP5(circFKBP5)的表达,后者可海绵化/抑制miR-513a-5p,而miR-513a-5p通过直接结合PD-L1的3'UTR抑制其表达,从而对NK细胞的免疫监视产生负面影响。来自体外细胞系和体内小鼠模型的临床前数据表明,使用sh-RNA或抗PD-L1抗体靶向PD-L1可增强高剂量DHT效应,从而更好地抑制CRPC细胞生长。这些发现可能有助于我们开发新疗法,通过将高剂量雄激素与PD-1/PD-L1检查点抑制剂联合使用,更好地抑制CRPC进展。

展开英文摘要原文

Most advanced prostate cancer (PCa) patients initially respond well to androgen deprivation therapy, but almost all eventually develop castration-resistant prostate cancer (CRPC). Early studies indicated the bipolar androgen therapy via a cycling of high dose and low dose of androgen to suppress PCa growth might be effective in a select patient population. The detailed mechanisms, however, remain unclear.

Here we found the capacity of natural killer (NK) cells to suppress the CRPC cells could be suppressed by a high dose of dihydrotestosterone (DHT). Mechanism dissection indicates that transactivated AR can increase circularRNA-FKBP5 (circFKBP5) expression, which could sponge/inhibit miR-513a-5p that suppresses the PD-L1 expression via direct binding to its 3'UTR to negatively impact immune surveillance from NK cells.

Preclinical data from in vitro cell lines and an in vivo mouse model indicate that targeting PD-L1 with sh-RNA or anti-PD-L1 antibody can enhance the high dose DHT effect to better suppress CRPC cell growth.

These findings may help us to develop novel therapies via combination of high dose androgen with PD-1/PD-L1 checkpoint inhibitors to better suppress CRPC progression.

论文信息

作者
Tang M、Sun Y、Huang CP、Chen L、Liu B、You B、Wang Z、Chang C
第一作者单位
Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210000, China.China
通讯作者单位
George Whipple Lab for Cancer Research, Departments of Pathology, Urology, Radiation Oncology and The Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, 14642 NY, USA. Chang@urmc.rochester.edu.United States
文献类型
非美国政府资助研究
期刊
Cell death & disease2022 Aug 29
原文标识
PubMed 36038573 · DOI 10.1038/s41419-022-04956-w